Home Back

Reducing Vascular Risk in Diabetic Patients

Type of Diabetes
Age
Statin Recommendation
ACEi/ARB Recommendation
ASA Recommendation
Recommend Liraglutide, Empagliflozin, Canagliflozin

Result Interpretation

This tool is developed based on the 2018 Canadian Diabetes Prevention and Management Guidelines, which are updated every five years to provide healthcare professionals with the best and latest evidence-based clinical practice data.

Compared to non-diabetics, diabetes can significantly accelerate the progression and natural course of cardiovascular disease. Health behavior interventions and pharmacological treatments aimed at reducing cardiovascular disease risk can significantly reduce the morbidity and mortality of patients, making it an important measure in diabetes treatment.

Favorite